1
|
Evenden P, Vandoolaeghe Q, Lecluse Y, Gac AC, Delépée R, Weiswald LB, Boutet-Robinet E, Boulanger M, Bonassi S, Lebailly P, Meryet-Figuière M. Agricultural exposures and DNA damage in PBMC of female farmers measured using the alkaline comet assay. Int Arch Occup Environ Health 2024; 97:353-363. [PMID: 38430240 PMCID: PMC10999382 DOI: 10.1007/s00420-024-02049-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/22/2024] [Indexed: 03/03/2024]
Abstract
OBJECTIVE Several studies investigated the link between agricultural occupational exposures and DNA damage, in an attempt to bring elements of biological plausibility to the increased cancer risk associated with them. However, only a few of these studies focused on females. METHODS The comet assay was performed on PBMC (Peripheral Blood Mononuclear Cells) samples from 245 females working in open field farming and cattle raising, located in the Normandy area of France. Individual questionnaires on tasks performed were administered at the time of sampling to directly assess exposures. Environmental exposures were issued from a questionnaire assessing the farm productions. Linear regression analyses were done using the DNA damage scores. RESULTS Regarding direct exposures, several tasks associated with exposure to potentially harmful chemicals were not associated with DNA damage, but a longer duration of use of herbicide on meadows (p = 0.05) or of cleaning and upkeep of agricultural equipment (p = 0.06) revealed higher DNA damage levels, although the number of exposed women was low. Several indirect and/or environmental exposures were associated with DNA damage in multivariate analyses: a larger surface of meadows (p = 0.006) or the presence of poultry (p = 0.03) was associated with less DNA damage, while the presence of swine (p = 0.01) was associated with higher DNA damage. Smokers and former smokers had less DNA damage than non-smokers (p = 0.0008 and p = 0.03). CONCLUSIONS We report modified levels of DNA damage for those environmentally exposed to meadows, poultry and pig farming, underlining the need for a better knowledge of the potential health risks experienced by females in this setting.
Collapse
Affiliation(s)
- P Evenden
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Q Vandoolaeghe
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - Y Lecluse
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - A C Gac
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - R Delépée
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - L B Weiswald
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - E Boutet-Robinet
- Toxalim (Research Centre in Food Toxicology), INRAE, ENVT, INP-Purpan, UPS, Université de Toulouse, Toulouse, France
| | - M Boulanger
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - S Bonassi
- Department of Human Sciences and Quality of Life Promotion, San Raffaele University, Rome, Italy
- Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Roma, Rome, Italy
| | - P Lebailly
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France
| | - M Meryet-Figuière
- Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for Cancer Prevention and Treatment), Normandie Univ, Université de Caen Normandie, Caen, France.
- Comprehensive Cancer Center François Baclesse, UNICANCER, Caen, France.
| |
Collapse
|
2
|
Ghesquières H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac AC, Guidez S, Touati M, Laribi K, Morschhauser F, Bonnet C, Waultier-Rascalou A, Orsini-Piocelle F, André M, Fournier M, Morand F, Berriolo-Riedinger A, Burroni B, Damotte D, Traverse-Glehen A, Quittet P, Casasnovas O. The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients. Blood 2024; 143:983-995. [PMID: 37979133 DOI: 10.1182/blood.2023021564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 10/10/2023] [Accepted: 10/29/2023] [Indexed: 11/19/2023] Open
Abstract
ABSTRACT Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, prospective, phase 2 study, we investigated a new firstline therapy regimen comprising 6 cycles of prednisone (40 mg/m2, days 1-5), vinblastine (6 mg/m2, day 1), doxorubicin (40 mg/m2, day 1), and bendamustine (120 mg/m2, day 1) (PVAB regimen) every 21 days for patients with newly diagnosed cHL aged ≥61 years with an advanced Ann Arbor stage. A Mini Nutritional Assessment score ≥17 was the cutoff value for patients aged ≥70 years. The primary end point was the complete metabolic response (CMR) rate after 6 cycles. The median age of the 89 included patients was 68 years (range, 61-88 years), with 35 patients (39%) aged ≥70 years. Seventy-eight patients (88%) completed the 6 cycles. The toxicity rate was acceptable, with a 20% rate of related serious adverse events. CMR was achieved by 69 patients (77.5%; 95% confidence interval [CI], 67-86). After a median follow-up of 42 months, 31 patients progressed or relapsed (35%), and 24 died (27%) from HL (n = 11), toxicity during treatment (n = 4), secondary cancers (n = 6), or other causes (n = 3). The 4-year progression-free survival (PFS) and overall survival rates were 50% and 69%, respectively. Multivariate analysis showed that liver involvement (P = .001), lymphopenia (P = .001), CRP (P = .0005), and comedications (P = .003) were independently associated with PFS. The PVAB regimen yielded a high CMR rate with acceptable toxicity. Over long-term follow-up, survival end points were influenced by unrelated lymphoma events. This trial was registered at www.clinicaltrials.gov as #NCT02414568 and at EudraCT as 2014-001002-17.
Collapse
Affiliation(s)
- Hervé Ghesquières
- Department of Hematology, Hopital Lyon Sud, Claude Bernard Lyon 1 University, Pierre Benite, France
| | - Daphné Krzisch
- Department of Hematology, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Paris, France
| | | | - Salim Kanoun
- Department of Hematology, Cancer Research Center of Toulouse, Team 9, INSERM Unité Mixte de Recherche 1037, Toulouse, France
| | - Anne Claire Gac
- Department of Hematology, Institut d'Hematologie de Basse Normandie, Caen, France
| | - Stéphanie Guidez
- Hematology Department, Centre Hospitalier Universitaire, Poitiers, France
| | - Mohamed Touati
- Department of Hematology, Hôpital Dupuytren, Centre Hospitalier Universitaire, Limoges, France
| | - Kamel Laribi
- Hematology Department, Centre Hospitalier, Le Mans, France
| | - Franck Morschhauser
- Department of Hematology, Centre Hospitalier Universitaire Lille, Universite de Lille, ULR 7365 Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France
| | | | | | | | - Marc André
- Department of Hematology, Centre Hospitalier Universitaire, Université Catholique de Louvain Namur, Université Catholique de Louvain, Yvoir, Belgium
| | - Marguerite Fournier
- Department of Statistics, Lymphoma Study Association Clinical Research, Hopital Lyon Sud, Pierre Benite, France
| | - Fabienne Morand
- Department of Statistics, Lymphoma Study Association Clinical Research, Hopital Lyon Sud, Pierre Benite, France
| | | | - Barbara Burroni
- Department of Pathology, Université de Paris Cité, Centre de Recherche des Cordeliers UMRS U1138 et GH Paris Centre APHP, Paris, France
| | - Diane Damotte
- Department of Pathology, Université de Paris Cité, Centre de Recherche des Cordeliers UMRS U1138 et GH Paris Centre APHP, Paris, France
| | | | - Philippe Quittet
- Department of Hematology, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Olivier Casasnovas
- Department of Hematology, University Hospital F. Mitterrand and INSERM Unité Mixte de Recherche 1231, Dijon, France
| |
Collapse
|
3
|
Delapierre B, Reman O, Dina J, Breuil C, Bellal M, Johnson-Ansah H, Gac AC, Damaj G, Chantepie S. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation. Curr Res Transl Med 2019; 67:145-148. [PMID: 30871955 DOI: 10.1016/j.retram.2019.03.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Revised: 03/05/2019] [Accepted: 03/07/2019] [Indexed: 11/28/2022]
Abstract
INTRODUCTION The most used preemptive therapy for Epstein Barr virus reactivation post allogeneic hematopoietic stem cell (HSCT) transplant is Rituximab, 375 mg/m2, once weekly until EBV viremia negativity. There is no data suggesting such a high dose. OBJECTIVE We hypothesized that a lower dose of Rituximab would be as efficient with less toxicity. PATIENTS In a retrospective, monocentric study, we analyzed 16 consecutive patients treated preemptively with low dose Rituximab for EBV reactivation post HSCT. Patients were treated with low Rituximab dose of 100 mg/m² weekly. Success was defined by a decrease of EBV viremia of 1 log10 and below 1000 UI/ml, and the absence of post-transplant lymphoproliferative disorder (PTLD). RESULTS Success rate was 93.4% (15/16). One (1/16, 6%) PTLD was diagnosed after preemptive therapy, despite a negative viremia. CONCLUSION A low dose of Rituximab of 100 mg/m² per injection for pre-emptive therapy of EBV reactivation post HSCT is safe and effective for preventing PTLD. Prospective, randomized, multicentric trials with larger number of patient are needed to determine the best rituximab dose.
Collapse
Affiliation(s)
- B Delapierre
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - O Reman
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - J Dina
- CHU de Caen, Department of Virology, Normandie Univ, 1400 Caen, France
| | - C Breuil
- Pharmacie du Centre Hospitalo-universitaire (CHU) de Caen, 14000, Caen, France
| | - M Bellal
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - H Johnson-Ansah
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - A C Gac
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - G Damaj
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France
| | - S Chantepie
- Normandie Univ, UNICAEN, CHU de Caen Normandie, 14000 Caen, France.
| |
Collapse
|
4
|
Audemard A, de la Gastine B, Chantepie S, Verger H, Gac AC, Bergot E, Reman O. [Dasatinib-related pneumonia? An example of pharmacovigilance survey]. Rev Mal Respir 2015; 32:84-6. [PMID: 25618211 DOI: 10.1016/j.rmr.2014.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Accepted: 05/26/2014] [Indexed: 10/24/2022]
Affiliation(s)
- A Audemard
- Service de médecine interne, CHU Côte-de-Nacre, avenue Côte-de-Nacre, 14000 Caen, France.
| | - B de la Gastine
- Centre régional de pharmacovigilance, CHU Côte-de-Nacre, 14000 Caen, France
| | - S Chantepie
- Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France
| | - H Verger
- Service de pneumologie, CHU Côte-de-Nacre, 14000 Caen, France
| | - A C Gac
- Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France
| | - E Bergot
- Service de pneumologie, CHU Côte-de-Nacre, 14000 Caen, France
| | - O Reman
- Service d'hématologie, CHU Côte-de-Nacre, 14000 Caen, France
| |
Collapse
|
5
|
Gac AC, Parienti JJ, Chantepie S, Cheze S, Johnson-Ansah H, Benabed K, Macro M, Lefevre V, Batho A, Fruchart C, Reman O. Predictive factors for a single successful cytapheresis session during the first mobilisation. Leuk Res 2014; 38:1020-4. [PMID: 25073661 DOI: 10.1016/j.leukres.2014.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 04/28/2014] [Accepted: 05/02/2014] [Indexed: 11/17/2022]
Abstract
To avoid repeated apheresis, the objective of this study was to analyse the predictive factors for a single successful cytapheresis during the first mobilisation. The pre-collection characteristics of 170 lymphoma and 95 myeloma patients were analysed. Among 60 lymphoma patients who had less than 30 CD34 cells/mm(3) the day before the first apheresis, an increase in the CD34 cell count between Day -1 and Day 1 was predictive of first stem cell mobilisation success, with a sensitivity of 100% if the Day 1 was higher than 30/mm(3) (10/60 patients). Success rate of obtaining an appropriate number of stem cells in one apheresis was 120 among 170 patients.
Collapse
Affiliation(s)
- A C Gac
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France; Université Caen, France.
| | - J J Parienti
- Université Caen, France; Etablissement Français du Sang, Caen, France; Centre de Lutte contre le Cancer François Baclesse, Caen, France; Unité de Biostatistiques, Centre Hospitalier Universitaire, Caen, France
| | - S Chantepie
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - S Cheze
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - H Johnson-Ansah
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - K Benabed
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - M Macro
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| | - V Lefevre
- Etablissement Français du Sang, Caen, France
| | - A Batho
- Etablissement Français du Sang, Caen, France
| | - C Fruchart
- Centre de Lutte contre le Cancer François Baclesse, Caen, France
| | - O Reman
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Caen, France
| |
Collapse
|